Compromised Peak Bone Mass in Patients with Inflammatory Bowel Disease—A Prospective Study

Saila Laakso, MD, PhD1, Helena Valta, MD, PhD1, Matti Verkasalo, MD, PhD1, Sanna Toiviainen-Salo, MD, PhD2, and Outi Mäkitie, MD, PhD1,3,4

Objective To evaluate peak bone mass attainment in children and adolescents with inflammatory bowel disease and to identify risk factors for suboptimal bone mass attainment.

Study design We conducted a prospective follow-up study of 47 children and adolescents (24 males) with ulcerative colitis (n = 30) or Crohn’s disease (n = 17). They were assessed for lumbar spine areal bone mineral density (aBMD) and for height-adjusted whole body less head bone mineral content (BMC); the values were corrected for bone age.

Results Altogether, 73% of the patients had completed pubertal development after the median follow-up time of over 5 years. Despite clinical inactivity of the disease in 70% of the patients at the follow-up visit, BMD or BMC Z-scores improved in none of the measurement sites. Lumbar spine aBMD Z-scores (mean difference [95% CI], −0.47 [−0.92 to −0.03]; P = .04) and whole body less head BMC height– and bone age–adjusted Z-scores (−0.52 [−1.01 to −0.02]; P = .04) decreased in patients who were pubertal at baseline and completed their pubertal development during the follow-up. Postpubertal patients had lower aBMD and BMC Z-scores in comparison with prepubertal and pubertal patients. Low lumbar spine aBMD (Z-score < −1.0) was associated with completed pubertal development, underweight, and greater lifetime cumulative weight-adjusted prednisolone dose. Vertebral fractures were detected in 3 patients (6%). One-fourth of the patients had insufficient serum 25-hydroxyvitamin D concentrations (<50 nmol/L).

Conclusions The longitudinal follow-up over the pubertal years shows that inflammatory bowel disease poses a significant threat for bone health. The suboptimal peak bone mass attainment may have life-long consequences. (J Pediatr 2014;164:1436-43).

Inflammatory bowel disease (IBD) is a risk for normal growth and pubertal development; inflammation, malnutrition, and glucocorticoid (GC) treatment contribute to these and to impaired bone health.1-4 Longitudinal studies indicate that bone mass accrual is subnormal.5-7 Premenopausal women with Crohn’s disease (CD) with disease onset before age 16 years demonstrated significantly reduced areal bone mineral density (aBMD).8 Two longitudinal studies with peripheral quantitative computed tomography (pQCT) showed in pediatric patients with CD or ulcerative colitis (UC), incomplete improvements in muscle mass, trabecular volumetric bone mineral density (vBMD), and bone geometry after median 1 and 2.6 years’ follow-up.9,10 The 1-year prospective study from diagnosis demonstrated greater increases in vBMD in prepubertal and early pubertal subjects with CD compared with more mature subjects.9 Follow-up times in previous studies have been short and bone health in young adults with childhood onset IBD thus remains unknown.

We conducted a prospective follow-up study of more than 5 years in children and adolescents with IBD. Most of the patients completed pubertal development during the follow-up. Disease characteristics, treatments, growth, and pubertal development were correlated with bone mass measurements to identify risk factors for low BMD.
This prospective cohort study involved 47 (24 males) children, adolescents, and young adults with IBD, diagnosed according to the Lennard-Jones criteria. Altogether, 80 (43 females) patients participated in baseline assessment between June 2004 and December 2005 and 47 (59%) of them in the follow-up examination between May 2010 and December 2010. Participants and nonparticipants did not differ in age, pubertal state, diagnosis, disease duration or activity, aBMD Z-scores, frequency of delayed bone age (BA), or cumulative prednisolone dose for the previous 3 years. At baseline, all patients were treated at the Outpatient Clinic for Pediatric Gastroenterology at the Children’s Hospital, Helsinki University Central Hospital. The inclusion criteria were age between 4 and 20 years and IBD diagnosed at least 3 months before enrollment. Subjects were ineligible if they had other medical conditions unrelated to IBD that could affect growth or bone mass accrual. The study protocol was approved by the institutional research ethics committee. A written informed consent was obtained from all participants and/or their guardians.

Medical records were reviewed for disease and treatment characteristics. Disease duration was calculated from the date of the first diagnostic gastroenterological endoscopy. Lifetime weight-adjusted (dose per body weight) cumulative exposure of orally and parenterally administered prednisolone equivalents was calculated. Fracture history, including localization and trauma mechanism, were recorded. Fractures resulting from falls from standing height or less were regarded low-energy fractures. A 3-day dietary recall was obtained for 33 (70%) patients; they were analyzed using the Finnish National Food Composition Database (Fineli; National Institute of Health and Welfare, Helsinki, Finland), and dietary and total (including supplements) intakes of calcium (Ca) and vitamin D were calculated.

Patients were clinically assessed; imaging studies and laboratory measurements were performed at the same visit. Pubertal status was determined according to Tanner staging. Age at menarche was determined by interview. Disease activity was scored in CD with Pediatric Crohn’s Disease Activity Index (PCDAI) before age 20 years and Harvey-Brashaw Index (HBI) in adults, and in UC with Pediatric Ulcerative Colitis Activity Index (PUCAI) in adolescents and Simple Clinical Colitis Activity Index (SCCAI) in adults. The patients were classified as having: (1) “moderate/severe disease” at examination, if PCDAI was ≥30, HBI ≥8, PUCAI ≥35, or SCCAI ≥5; (2) “mild disease” if PCDAI ≥10 and <30, HBI ≥5 and <8, PUCAI ≥10 and <35, or SCCAI >2 and <5; or (3) “inactive disease” if PCDAI <10, HBI <5, PUCAI <10, or SCCAI ≤2.

Growth Assessment

Height was measured with a Harpenden stadiometer (Hol- tain Limited, Crymych, United Kingdom) and weight in thin underwear with an electric scale. Height Z-score was defined as a deviation of height, in SD scores, from the mean height for age and sex. Patients <18 years were regarded underweight, normal weight, or overweight according to Finnish pediatric body mass index references. Adults were classified underweight, normal weight, or overweight by body mass index <18.5 kg/m², 18.5-25 kg/m², or >25 kg/m², respectively. Parental heights were obtained from medical records and parent-specific expected height SD scores were calculated.

Imaging Studies

BA was determined for prepubertal and pubertal patients (n = 17) from a left hand radiograph and considered delayed or advanced when it differed from calendar age more than 1 year; BA-adjusted BMD, bone mineral content (BMC), and height values were used in these cases. aBMD (g/cm²), BMC (g), lean mass (LM), and fat mass (FM) were measured at both time points with dual-energy X-ray absorptiometry (DXA; pediatric software, Discovery A, version 12.4; Hologic, Bedford, Massachusetts). Calibration of the measurements was performed by using a spine phantom; inter-assay coefficient of variation for the phantom BMC, area, and BMD were 0.35%, 0.21%, and 0.41%, respectively. Lumbar spine (L1-L4) aBMD values were transformed into Z-scores by comparing with age- and sex-adjusted reference data for white subjects in the US. We calculated height-adjusted Z-scores for whole body less head BMC values using the least mean square algorithm with age- and sex-adjusted reference data for nonblack subjects for ages 5-20 years. Z-scores for LM for height (age <20 years), ratio of LM to height² (age ≥20 years), percent FM for age (age <20 years), and ratio of FM to height² (age ≥20 years) were calculated using the least mean square algorithm.

Spinal compression fractures were determined from lateral spinal radiographs and from DXA-derived vertebral fracture assessment (VFA) images. Vertebral fractures (VF) were graded as mild (Grade 2a; 20%-49% anterior height reduction) or severe (2b; 50% anterior height reduction) wedge deformities, or mild (3a; vertebral middle and/or posterior height reduction 20%-29%) or severe (3b; vertebral middle and/or posterior height reduction ≥30%) compression deformities. The VFA and radiograph images were assessed independently by two experienced readers; discrepancies were reviewed for consensus.

Biochemistry

Blood count and erythrocyte sedimentation rate, plasma Ca, phosphate, alkaline phosphatase and albumin, and serum testosterone, estradiol, and dehydroepiandrosteronesulfate were measured by standard methods. Serum 25-hydroxyvitamin D [25(OH)D] was assessed by liquid chromatography; the laboratory’s reference range was >40 nmol/L and target level in children 50-150 nmol/L, and plasma fasting parathyroid hormone (P-PTH) by an immunometric assay (IMMULITE 2000; Diagnostic Products, Los Angeles, California); the reference range was 8-73 ng/L. Urine was analyzed for Ca/creatinine.
Altogether 47 patients (24 males) were prospectively followed from median age of 14.5 years to this follow-up assessment at the median age of 19.7 years; 30 patients (64%) had UC, and 17 (36%) had CD (Table I). At the follow-up visit, mean disease duration was 8.6 years, the majority (>70%) had inactive disease, and 11 (23%) used no daily oral medication for IBD.

**Results**

At the time of diagnosis, 25 of the patients were prepubertal, 20 pubertal, and two postpubertal. At follow-up, the majority (75%) had completed pubertal development. Six (13%) subjects had delayed BA (4 boys). Median age at menarche in postpubertal girls (n = 19) was 14 years (range, 12-20 years). The patient with latest menarche had otherwise-normal puberty, whereas 2 postpubertal boys had preadrenarchal testosterone and estradiol levels were appropriate for puberty but primary amenorrhea. In one boy, puberty was induced with testosterone in 6 months. Serum dehydroepiandrosteronesulfate levels (<1.0 µg/L) was measured in 3 patients. Plasma alkaline phosphatase was above the age- and sex-specific reference values in 5 patients. One of the patients with abnormalities in laboratory tests had tubulointerstitial nephritis and secondary hyperparathyroidism (P-PTH 239 ng/L), and others had no metabolic bone disease unrelated to IBD.

Low lumbar spine BA-adjusted aBMD (0.8 mM) was measured in 3 patients. Plasma alkaline phosphatase was above the age- and sex-specific reference values in 5 patients. One of the patients with abnormalities in laboratory tests had tubulointerstitial nephritis and secondary hyperparathyroidism (P-PTH 239 ng/L), and others had no metabolic bone disease unrelated to IBD.

Low lumbar spine BA-adjusted aBMD (<1.0 Z-score) was observed in 17 (36%) patients. Patients with low lumbar spine aBMD were all postpubertal, more often overweight, and had lower height SDS and LM Z-scores than those with greater aBMD (Table III). Lifetime cumulative weight-adjusted prednisolone dose was significantly greater and cumulative duration of GC treatment longer among patients with low aBMD. When we restricted analysis to postpubertal subjects, low lumbar spine BA-adjusted aBMD was associated with greater cumulative weight-adjusted prednisolone dose (P = .002), longer lifetime duration of GC treatment (P = .02), underweight (P = .03), lower height (P = .008), and LM Z-scores (P = .006).

**Bone Mass Accrual, Growth, and Vitamin D Status over Follow-Up Time**

No improvement in bone mineral accrual rate was found in any site of measurement during follow-up (Figure). In the
Reflecting disease activity during the follow-up, did not \( P = .006 \). Cumulative weight-adjusted prednisolone dose, examination \( (t) \) plotted on the basis of the pubertal state at first \( \text{pubertal} \) examination \( (n = 8) \), the corresponding change in Z-scores was on average \( -0.20 \) \((-0.73 \text{ to } 0.33, P = .37) \). Altogether, 23 patients had inactive disease at both baseline and follow-up assessments. Their whole body less head BMC BA- and height-adjusted Z-scores also decreased during follow-up \(-0.5 \) \([-0.9 \text{ to } -0.2] \), \( P = .006 \). Cumulative weight-adjusted prednisolone dose, reflecting disease activity during the follow-up, did not correlate with the changes in lumbar spine aBMD BA- adjusted Z-scores \( (t = -0.04, P = .78) \) or whole body less head BMC BA- and height-adjusted Z-scores \( (t = -0.07, P = .64) \). To estimate the bone mineral accrual according to pubertal development, BA-adjusted aBMD and BMC Z-scores at the 2 time points were plotted on the basis of the pubertal state at first examination \( (\text{Figure}) \). There was no improvement seen during follow-up time in the BA-adjusted aBMD or BMC Z-scores in patients who were prepubertal at first examination; 10 of them were pubertal at second examination and two remained prepubertal (total \( n = 14 \)). Lumbar spine aBMD Z-scores \( (\text{mean difference [95% CI], } -0.47 \text{ [-0.92 to } -0.03]) \) and whole body less head BMC height- and BA-adjusted Z-scores \( (-0.52 \text{ [-1.01 to } -0.02]) \) decreased in patients who were pubertal at the beginning of the study and completed pubertal development during the follow-up \( (n = 17) \). Whole body less head BMC height-adjusted Z-scores decreased in patients who were postpubertal already at baseline \( (n = 14; -0.31 \text{ [-0.61 to } 0.006]) \).

The BA-adjusted height Z-score did not change significantly during the follow-up in the whole cohort \( (\text{mean difference [95% CI], } 0.05 \text{ [-0.2 to } 0.3], P = .62) \) or when analyzed separately for the patients treated with tumor necrosis factor-\( \alpha \) antibodies at the time of follow-up assessment \( (n = 8, 0.4 \text{ [-0.4 to } 1.2], P = .26). Change in height SDS (median \([\text{range}], 0 \text{ [-1.4 to } 2.0]\)) correlated positively with change.

### Table II. aBMD and BMC Z-scores, and body composition in patients with pediatric onset of IBD altogether and according to pubertal states

<table>
<thead>
<tr>
<th>Characteristic Median (Range)</th>
<th>All ( P ) Value*</th>
<th>Prepubertal and pubertal, ( n = 12 )</th>
<th>Postpubertal, ( n = 33 )</th>
<th>( P ) Value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lumbar spine aBMD BA Z-score</td>
<td>( -0.7 \text{ [-3.3 to 3.3]} )</td>
<td>( &lt;.001 )</td>
<td>( -0.5 \text{ [-1.0 to 3.3]} )</td>
<td>( -1.1 \text{ [-3.3 to 0.7]} )</td>
</tr>
<tr>
<td>Whole body less head BMC HAZ-score</td>
<td>( -0.1 \text{ [-2.9 to 2.0]} )</td>
<td>.04</td>
<td>( 0.3 \text{ [-0.6 to 1.0]} )</td>
<td>( -0.3 \text{ [-2.9 to 2.0]} )</td>
</tr>
<tr>
<td>LM Z-score</td>
<td>( -0.5 \text{ [-2.6 to 1.2]} )</td>
<td>( &lt;.001 )</td>
<td>( -0.8 \text{ [-2.5 to 0.6]} )</td>
<td>( -0.4 \text{ [-2.6 to 1.2]} )</td>
</tr>
<tr>
<td>FM Z-score</td>
<td>( -0.9 \text{ [-4.5 to 1.5]} )</td>
<td>( &lt;.001 )</td>
<td>( -0.6 \text{ [-4.5 to 1.4]} )</td>
<td>( -1.0 \text{ [-2.8 to 0.8]} )</td>
</tr>
</tbody>
</table>

HAZ, height- and BA-adjusted Z-score.

*\( P \) values from one-sample \( t \) test.

†\( P \) values from independent samples \( t \) test comparing the group of prepubertal and pubertal patients to the group of postpubertal patients.

### Table III. Associations with low BA-adjusted lumbar spine aBMD \( (<-1.0 \text{ Z-score}) \) with disease characteristics, pubertal development, anthropometrics, nutrition, and fracture history

<table>
<thead>
<tr>
<th>Characteristic ( n ) (%) or median (range)</th>
<th>Normal lumbar spine aBMD ( (n = 28) )</th>
<th>Low lumbar spine aBMD ( (n = 17) )</th>
<th>( P ) Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (boy/girl)</td>
<td>13 (46%)/15 (54%)</td>
<td>9 (53%)/8 (47%)</td>
<td>.67</td>
</tr>
<tr>
<td>Diagnosis (UC/CD)</td>
<td>20 (71%)/8 (29%)</td>
<td>9 (53%)/8 (47%)</td>
<td>.21</td>
</tr>
<tr>
<td>Age, y</td>
<td>18.6 (10.7-25.0)</td>
<td>20.4 (16.6-24.3)</td>
<td>.03</td>
</tr>
<tr>
<td>Disease characteristic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of disease, y</td>
<td>7.9 (6.9-19.8)</td>
<td>9.1 (6.8-15.1)</td>
<td>.35</td>
</tr>
<tr>
<td>IBD activity (inactive/mild-severe)</td>
<td>21 (75%)/7 (28%)</td>
<td>11 (65%)/6 (35%)</td>
<td>.29</td>
</tr>
<tr>
<td>Lifetime cumulative weight-adjusted prednisolone dose, mg/kg, ( n = 44 )</td>
<td>132 (2.7-1320)</td>
<td>268 (1.8-1050)</td>
<td>.03</td>
</tr>
<tr>
<td>Lifetime duration of GC treatment, days, ( n = 44 )</td>
<td>379 (21-2507)</td>
<td>650 (21-4112)</td>
<td>.007</td>
</tr>
<tr>
<td>Pubertal development</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pubertal status at dg (pre-/pubertal/post-)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pubertal status at visit ( (pre-/pubertal/post-) )</td>
<td>2 (7%)/10 (36%)/16 (57%)</td>
<td>0/0/17 (100%)</td>
<td>.007</td>
</tr>
<tr>
<td>Anthropometrics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height SDS</td>
<td>0.6 (-1.3 to 3.1)</td>
<td>-0.5 (-2.8 to 0.9)</td>
<td>.002</td>
</tr>
<tr>
<td>LM Z-score</td>
<td>-0.4 (-2.5 to 1.2)</td>
<td>-1.0 (-2.6 to 0.7)</td>
<td>.05</td>
</tr>
<tr>
<td>FM Z-score</td>
<td>-0.6 (-4.5 to 1.4)</td>
<td>-1.1 (-2.7 to 0.4)</td>
<td>.15</td>
</tr>
<tr>
<td>Underweight/normal weight/overweight</td>
<td>1 (4%)/18 (64%)/9 (32%)</td>
<td>4 (24%)/13 (76%)/0</td>
<td>.009</td>
</tr>
<tr>
<td>Vitamin D, fracture history, and smoking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total vitamin D intake, ( \mu g/d )</td>
<td>11.1 (2.3-26.2)</td>
<td>21.7 (1.7-49.2)</td>
<td>.01</td>
</tr>
<tr>
<td>Serum 25(OH)D, nmol/L</td>
<td>59 (37-120)</td>
<td>75 (26-107)</td>
<td>.38</td>
</tr>
<tr>
<td>Fracture history lifetime (no/any)</td>
<td>20 (71%)/8 (29%)</td>
<td>11 (65%)/6 (35%)</td>
<td>.64</td>
</tr>
<tr>
<td>VF present</td>
<td>3 (11%)</td>
<td>0</td>
<td>.27</td>
</tr>
</tbody>
</table>

*\( P \) values from independent samples \( t \) test, except those marked with † that are from Mann-Whitney \( U \) test.
in lumbar spine aBMD Z-score in the whole cohort ($\tau = 0.33$, $P = .002$). Serum 25(OH)D levels and total vitamin D intake were greater at follow-up examination than at initial examination (Table IV; available at www.jpeds.com). Although only 47% of patients were initially examined during the summer, 85% of patients participated in the follow-up examination during the summer. The prevalence of vitamin D deficiency decreased from 30% to 7% during the follow-up. Patients with suboptimal serum 25(OH)D level (<50 nmol/L, n = 11) did not differ significantly in lumbar spine aBMD (median [range]: −0.8 [−3.3 to 0.5] vs −0.6 [−2.9 to 2.9], $P = .51$) or whole body less head BMC BA- and height-adjusted Z-score from those with higher serum 25(OH)D levels (−0.6 [−2.9 to 1.0] vs −0.1 [−2.5 to 2.0], $P = .43$).

Fracture History and Vertebral Fractures
Altogether, 8 peripheral fractures were reported in 7 patients during the follow-up. Two fractures resulted from a high-energy injury and 6 fractures from a low-energy injury. VFs were detected in three patients (6%); they were 21-25 years of age and all had UC with a disease duration ranging from 7.5 to 11.9 years. Single VF was found in 2 female patients and 7 VFs in a male patient; all fractures occurred in the thoracic region. One of the fractures was graded as mild anterior wedge deformity (2a), 2 as severe anterior wedge deformity (2b), and 6 as mild compression deformity (3a).

Discussion
IBD during childhood and adolescence puts normal growth and development of the skeleton at risk. During childhood and adolescence, bone mass increases to attain peak values by the end of the second or the beginning of the third decade; the greatest rate of mineral accumulation occurs during puberty. In our cohort, no improvement in bone mass accrual was observed during puberty. Moreover, lumbar spine aBMD Z-scores and whole body less head BMC height-and BA-adjusted Z-scores decreased significantly in patients who were pubertal at study onset and completed
pubertal development during follow-up. Postpubertal patients showed significantly decreased aBMD, indicating suboptimal peak bone mass attainment during puberty. Previous studies on premenopausal women have suggested that juvenile-onset IBD leads to suboptimal peak bone mass.\textsuperscript{6,32} There are scarce previous studies on children and adolescents with IBD in which investigators explore the influence of puberty on BMD development, although follow-up studies have shown insufficient improvement in bone health after initiation of IBD treatment.\textsuperscript{5-7,9,10} No significant change was seen in BMD during a 2-year follow-up from diagnosis in 48 patients with CD, of whom 72% were prepubertal or in early puberty at diagnosis.\textsuperscript{5} Greater improvements in trabecular vBMD Z-scores were demonstrated in subjects at Tanner stage I-II in comparison with those at Tanner stage III-V over 1-year follow-up by pQCT.\textsuperscript{9} However, a study following 102 children with IBD for 2.6 years by pQCT showed that improvements in height-corrected muscle cross-sectional area associated closely with bone measurements; the inclusion of pubertal maturation and lumbar spine bone mineral apparent density\textsuperscript{33} or whole body less head BMC.\textsuperscript{34} Studies exploring bone mineral accrual during puberty have used different classifications of pubertal stages, and subgroups have often had limited power to exclude negative findings. On the basis of these previous observations and our data, juvenile-onset IBD comprises a true risk for bone mass accrual during puberty. We have previously shown that in addition to patients with IBD, pediatric liver transplant recipients\textsuperscript{35} and adolescents who had undergone allogeneic stem cell transplantation\textsuperscript{36} have inadequate bone mass accrual during puberty. Delayed puberty is known to compromise peak bone mass permanently.\textsuperscript{37-38} Children and adolescents with IBD are at risk for delayed puberty and growth retardation because of malnutrition, GC therapy, and systemic inflammation.\textsuperscript{2,4} In our cohort, both increased age at menarche in girls and delayed BA in boys were observed as signs of pubertal delay at the follow-up visit. In addition to pubertal delay, growth retardation needs to be taken into account when exploring the impact of IBD on bone mass accrual. Regarding DXA results, there is a risk for underestimation of aBMD in children with reduced height. Although we adjusted whole body less head BMC Z-scores for both BA and height SDS, the values deteriorated significantly during the follow-up in the whole cohort. Height Z-scores at follow-up visit did not differ significantly from the expected heights calculated from parental heights, and no significant change in height Z-scores was observed during follow-up, in concordance with previous studies.\textsuperscript{39-42} In agreement with our results, improvements in height Z-scores have been correlated with higher bone mineral accrual rate.\textsuperscript{2,9} GC treatment in patients with IBD results in reduced bone formation by suppressing osteoblastogenesis, inhibiting chondrocyte proliferation and collagen synthesis, and by promoting bone resorption.\textsuperscript{4} In the follow-up assessment of our cohort, greater lifetime prednisolone dose was associated with low lumbar spine aBMD, reflecting possibly both more active disease and the side effects of GC treatment. The baseline data of the whole cohort of 80 patients indicated that cumulative weight-adjusted dose of prednisolone $\geq 150$ mg/kg for the preceding 3 years was associated with increased risk for low BA-adjusted aBMD Z-score.\textsuperscript{12} In other studies, cumulative GC dose has been associated with reduced aBMD\textsuperscript{43,45} and correlated negatively with the change in lumbar spine BMD Z-scores.\textsuperscript{46} However, many studies have found no association between GC treatment and bone measurements or bone mineral accrual rate.\textsuperscript{5-7,10,34,47,48} Our strength concerning analyses on the effects of GC treatment is the careful collection of data, making it possible to calculate reliable lifetime cumulative weight-adjusted GC doses including all orally and parenterally administered GCs. In addition to cumulative GC dose reflecting disease activity, we estimated clinical disease activity indexes only at baseline and follow-up assessments. aBMD Z-scores did not improve at any measurement site over the median follow-up time of over 5 years, although the disease was clinically inactive in most of the patients at the follow-up visit. Clinically inactive state of disease does not necessarily correlate with mucosal healing that was not routinely evaluated during the study.

As possible consequences of compromised bone strength, we found subclinical VFs in 11% of the 80 patients with IBD at baseline by assessing the VFA images.\textsuperscript{12} By using both radiography and VFA-images, we found, at the follow-up visit, VFs in 6% of the patients. An epidemiologic study on fracture risk in pediatric patients with IBD has shown a strong trend towards increased VFs in pediatric patients with IBD.\textsuperscript{59} In contrary to previous reports on VFs in patients with CD,\textsuperscript{50,51} all VFs in our cohort were found in patients with UC.

Total intake of vitamin D increased during the follow-up and fewer patients were vitamin D deficient in comparison with the baseline assessment. However, one fourth of the patients still had 25(OH)D concentrations less than 50 nmol/L, indicating a need for continuous monitoring of vitamin D status in patients with IBD. Patients with low lumbar spine aBMD had greater total vitamin D intake, but their serum 25(OH)D levels were not significantly greater, reflecting possibly impaired absorption of nutrients.

In conclusion, this longitudinal follow-up study on 47 patients with IBD over the pubertal years shows that IBD poses a significant threat for bone health during childhood and adolescence. The observed suboptimal peak bone mass attainment may have life-long consequences and predispose to symptomatic osteoporosis in early adulthood. More studies are needed to define mechanisms behind compromised bone mass accrual. Optimally, these studies should include larger cohorts, follow-up from disease onset to skeletal maturity, other methods in addition to DXA to assess skeletal characteristics, and interventions with vitamin D and weight-bearing exercise. Puberty may offer a window
of opportunity to improve BMD, although our study showed insufficient efforts during this critical period (eg, to ensure optimal vitamin D status).

We thank research nurses Päiviikki Rissanen and Nea Boman for their skillful assistance in this study.

Submitted for publication Oct 22, 2013; last revision received Dec 17, 2013; accepted Jan 29, 2014.

Reprint requests: Salla Laakso, MD, PhD, Children’s Hospital, P. O. Box 281, FI-00029 Helsinki University Central Hospital, Helsinki, Finland. E-mail: salla.laakso@helsinki.fi

References


Table IV. Serum 25(OH)D, dietary intake of vitamin D and Ca, and the frequency of vitamin D deficiency at baseline and follow-up assessments of young patients with IBD

<table>
<thead>
<tr>
<th>Characteristic, median (range) or n (%)</th>
<th>Baseline</th>
<th>Follow-up</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum 25(OH)D, nmol/L</td>
<td>49 (17-102)</td>
<td>67 (26-120)</td>
<td>.001</td>
</tr>
<tr>
<td>Season (summer)</td>
<td>22 (47%)</td>
<td>40 (85%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Dietary vitamin D intake, µg/day†</td>
<td>3.9 (0.9-11.5)</td>
<td>4.7 (1.1-24.5)</td>
<td>.16</td>
</tr>
<tr>
<td>Vitamin D supplement in use</td>
<td>24 (52%)</td>
<td>29 (63%)</td>
<td>.40</td>
</tr>
<tr>
<td>Total vitamin D intake, µg/day†</td>
<td>7.5 (1.6-19.5)</td>
<td>12.6 (1.7-49.2)</td>
<td>.002</td>
</tr>
<tr>
<td>Dietary Ca intake, µg/day†</td>
<td>962 (256-2820)</td>
<td>1120 (199-2830)</td>
<td>.27</td>
</tr>
<tr>
<td>Ca supplement in use</td>
<td>20 (43%)</td>
<td>20 (43%)</td>
<td>&gt;.99</td>
</tr>
<tr>
<td>Total Ca intake, µg/day†</td>
<td>1380 (678-2820)</td>
<td>1420 (287-3260)</td>
<td>.44</td>
</tr>
<tr>
<td>Vitamin D deficiency &lt;37.5 nmol/L</td>
<td>13 (30%)</td>
<td>3 (7%)</td>
<td>.01</td>
</tr>
<tr>
<td>Vitamin D insufficiency &lt;50 nmol/L</td>
<td>22 (51%)</td>
<td>11 (26%)</td>
<td>.03</td>
</tr>
</tbody>
</table>

*P values from paired-samples t test and 2-sample test for equality of proportions with continuity correction.
†Total n = 24.
‡Total n = 43.